Start Your Search
P2.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 966)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
P2.17-10 - Daily Low–Dose Cisplatin and High Dose Radiotherapy for Elderly Patients with Stage III NSCLC is Well Tolerated. (ID 13473)
16:45 - 18:00 | Author(s): C.C.E. Koning
To assess how daily low-dose Cisplatin(6mg/m²) combined with 66 Gy/24 fractions is tolerated by the elderly patient with stage III NSCLC.a9ded1e5ce5d75814730bb4caaf49419 Method
All patients with stage III NSCLC were selected (2005-2015). The Cox regression model was used to investigate the difference between the younger and elderly patient group concerning toxicity and survival. The Kaplan Meier method was used to show the difference between the dichotomized age factor.4c3880bb027f159e801041b1021e88e8 Result
The crude incidence of severe toxicity (STI) (grade 3-5) was 15% in patients ≤65 years (n=73) and 16% in patients >65 years (n=81)(Fig1). The median time to appearance of STI after treatment was 4 months. Age was a continuous variable in the Cox regression model. The p-value of age was 0.9 (HR=1.002,95%CI:0.968 –1.038) in univariate analysis and 0.4 (HR=1.02,95%CI:0.976–1.063) in multivariate analysis.The univariate analysis with factor age on overall survival showed a p-value of 0.2 (HR=1.01,95%CI:0.99-1.034) and in multivariate analysis a p-value of 0.06 (HR=1.02,95%CI:1.0-1.048) among other prognostic factors. Median follow-up was 31 months for patients ≤65 years and 16 months for patients >65 years(Fig2).
Daily low-dose cisplatin and high dose radiotherapy in stage III NSCLC is as tolerable for both young and older patients resulting in similar toxicity and overall survival.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.